Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5
In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin levels ≥ 2 g/dL (82.3% vs. 0%) and hemoglobin level ≥ 12 g/dL (67.7% vs. 0%), both in the absence of red blood cell transfusions, vs. patients who continued on anti-C5 treatment1,2
Fabhalta, now available for both previously treated and treatment-naïve patients, is the only FDA-approved Factor B inhibitor of the immune system's complement pathway, which drives complement-mediated hemolysis in PNH1,6
Significant unmet need remains in PNH, a chronic and rare blood disorder; despite anti-C5 therapy, a large proportion of patients can remain anemic and dependent on blood transfusions7,8
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
EAST HANOVER, N.J., Dec. 5, 2023 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1. Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]). In clinical trials, treatment with Fabhalta increased hemoglobin levels (≥ 2 g/dL from baseline in the absence of RBC transfusions) in the majority of patients and in APPLY-PNH nearly all patients treated with Fabhalta did not receive blood transfusions1-5.
Experience the full interactive Multichannel News Release here:
"An efficacious oral treatment with a demonstrated safety profile could be practice-changing for physicians and help relieve burdens experienced by people with PNH," said Vinod Pullarkat, MD, MRCP, Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. "In clinical studies, iptacopan was superior to anti-C5s in hemoglobin improvement in the absence of RBC transfusion and transfusion avoidance rate, and also effective in complement inhibitor-naïve individuals, by providing clinically meaningful hemoglobin-level increases without the need for blood transfusions."
The FDA approval is based on the Phase III APPLY-PNH trial in patients with residual anemia (hemoglobin < 10 g/dL) despite prior anti-C5 treatment who switched to Fabhalta, which demonstrated superiority in hemoglobin improvement in the absence of RBC transfusions and in transfusion avoidance rate over patients who stayed on anti-C5 treatments1,2. Approval was also supported by the Phase III APPOINT-PNH study in complement inhibitor-naïve patients1,3. The 24-week core treatment periods in APPLY-PNH and APPOINT-PNH trials respectively showed1-3:
Patients with sustained increase of hemoglobin levels ≥ 2 g/dLa from baseline in the absence of transfusions: 82.3% of anti-C5-experienced Fabhalta patients responded vs. 0% for anti-C5 (difference of 81.5%b, P<0.0001); 77.5% of complement inhibitor-naïve patients using Fabhalta achieved this outcome (sensitivity analysis showed 87.5%c)1-3.
Patients with sustained hemoglobin level ≥ 12 g/dLa in the absence of transfusions: 67.7% of anti-C5-experienced Fabhalta patients responded vs. 0% for anti-C5 (difference of 66.6%b, P<0.0001)1-2.
Patients avoiding transfusiond,e: Transfusion avoidance rate 95.2% for anti-C5-experienced Fabhalta patients vs. 45.7% for anti-C5 (difference of 49.5%b, P<0.0001)1-2.
In the APPLY-PNH trial, the most commonly reported (≥10%) adverse reactions (ARs) with Fabhalta vs. anti-C5s were: headachef (19% vs. 3%), nasopharyngitisg (16% vs. 17%), diarrhea (15% vs. 6%), abdominal painf (15% vs. 3%), bacterial infectionh (11% vs. 11%), nausea (10% vs. 3%), and viral infectioni (10% vs. 31%)1,2. In the APPOINT-PNH trial, the most commonly reported ARs (≥10%) were headachef (28%), viral infectioni (18%), nasopharyngitisg (15%), and rashj (10%)1,3. In APPLY-PNH, serious ARs were reported in two (3%) patients with PNH receiving Fabhalta, which included pyelonephritis, urinary tract infection and COVID-191,2. In APPOINT-PNH, serious ARs were reported in two (5%) patients with PNH receiving Fabhalta, which included COVID-19 and bacterial pneumonia1,3. Fabhalta may cause serious infections caused by encapsulated bacteria and is available only through a Risk Evaluation and Mitigation Strategy (REMS) that requires vaccinations for encapsulated bacteria1.
People with PNH have an acquired mutation making red blood cells susceptible to premature destruction by the complement system6,8. PNH is characterized by hemolysis, bone marrow failure, and thrombosis in varying combinations and levels of severity6-8. Existing C5 inhibitor treatments, administered as infusions, may leave PNH symptoms uncontrolled7,8. Up to 88% of patients on anti-C5 treatment may have persistent anemia with over one-third of those patients requiring blood transfusions at least once per year7,8.
"The U.S. approval of Fabhalta is an extraordinary moment for people living with PNH, their loved ones and the healthcare providers who care for them," said Victor Bultó, President US, Novartis. "This new, effective oral medicine may mean that patients can reset their expectations of living with PNH, a chronic and life-altering blood disease. As Novartis continues to focus on conditions with unmet patient need, we are exploring the potential of Fabhalta in other complement-mediated diseases – with an ultimate goal to drive meaningful change for patients."
Discovered and developed by Novartis, Fabhalta is expected to be available in the United States in December. Additional regulatory filings and reviews for Fabhalta in PNH are currently underway around the world.
aAssessed between Day 126 and Day 168. bAdjusted difference in proportion. cSensitivity analysis incorporates data from local labs when central labs were not available. dAssessed between Day 14 and Day 168. eTransfusion avoidance is defined as absence of administration of packed-red blood cell transfusions between Day 14 and Day 168. fIncludes similar terms. gNasopharyngitis contains: rhinitis allergic, upper respiratory tract infection, pharyngitis, rhinitis. hBacterial infection contains: pyelonephritis, urinary tract infection, bronchitis bacterial, bronchitis haemophilus, cholecystitis, folliculitis, cellulitis, arthritis bacterial, sepsis, klebsiella infection, staphylococcal infection, Pseudomonas infection, hordeolum, pneumonia bacterial. iViral infection contains: COVID-19, herpes zoster, oral herpes, nasal herpes, influenza A virus test positive, influenza. jRash: dermatitis allergic, acne, erythema multiforme, rash maculo-papular, rash erythematous.
Indication
FABHALTA is a prescription medicine used to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).
It is not known if FABHALTA is safe and effective in children.
Important Safety Information
FABHALTA is a medicine that affects part of the immune system and may lower one's ability to fight infections. FABHALTA increases the chance of getting serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or fatal if not recognized and treated early. Patients must complete or update vaccinations against these bacteria at least 2 weeks before starting FABHALTA. If patients have not completed these vaccinations and FABHALTA therapy must be started right away, they should receive the required vaccinations as soon as possible. If patients have not been vaccinated and FABHALTA must be started right away, they should also receive antibiotics to take for as long as their doctor tells them. If patients have been vaccinated against these bacteria in the past, they might need additional vaccinations before starting FABHALTA. Their doctor will decide if they need additional vaccinations. Vaccines do not prevent all infections caused by encapsulated bacteria. Patients should call their doctor or get emergency medical care right away if they have any of these signs and symptoms of a serious infection: fever with or without shivers or chills; fever with chest pain and cough; fever with high heart rate; headache and fever; confusion; clammy skin; fever and a rash; fever with breathlessness/fast breathing; headache with nausea or vomiting; headache with stiff neck or stiff back; body aches with flu-like symptoms; or eyes sensitive to light. Doctors will give their patients a Patient Safety Card about the risk of serious infections. Patients must carry it with them at all times during treatment and for 2 weeks after their last dose of FABHALTA. The risk of serious infections may continue for a few weeks after their last dose of FABHALTA. It is important for patients to show this card to any doctor who treats them. This will help doctors diagnose and treat patients quickly.
FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before patients can take FABHALTA, their doctor must enroll in the FABHALTA REMS program, counsel patients about the risk of serious infections caused by certain bacteria, give patients information about the symptoms of serious infections, make sure that patients are vaccinated against serious infections caused by encapsulated bacteria and that they receive antibiotics if they need to start FABHALTA right away and are not up to date on vaccinations, as well as give patients a Patient Safety Card about the risk of serious infections.
Since FABHALTA may increase patients' cholesterol and triglycerides, their doctor will do blood tests to check their levels periodically.
Patients should not take FABHALTA if they are allergic to FABHALTA or any of the ingredients in FABHALTA. Patients should not take FABHALTA if they have a serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B when starting FABHALTA.
Before taking FABHALTA, patients should tell their doctor about all their medical conditions, including if they have an infection or fever, have kidney or liver problems, are pregnant or plan to become pregnant (it is not known if FABHALTA will harm an unborn baby), or are breastfeeding or plan to breastfeed as it is not known if FABHALTA passes into breast milk. Patients should not breastfeed during treatment and for 5 days after the last dose of FABHALTA.
Patients should tell their doctor about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking FABHALTA with certain other medicines may affect the way FABHALTA works and may cause side effects. Patients should know the medicines they take and the vaccines they receive. Patients should keep a list of them to show their doctor and pharmacist when they get a new medicine.
If patients have PNH and stop taking FABHALTA, their doctor will need to monitor them closely for at least 2 weeks after stopping FABHALTA. Stopping treatment with FABHALTA may cause a breakdown of red blood cells due to PNH. Symptoms or problems that can happen due to breakdown of red blood cells include decreased hemoglobin level in the blood; blood in the urine; shortness of breath; trouble swallowing; tiredness; pain in the stomach (abdomen); blood clots, stroke, and heart attack; and erectile dysfunction (ED). It is important that patients take FABHALTA exactly as their doctor tells them to lower the possibility of breakdown of red blood cells due to PNH.
The most common side effects of FABHALTA include headache; nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis); diarrhea; pain in the stomach (abdomen); infections (viral and bacterial); nausea; and rash.
批准的依據是 APPLY-PNH 試驗,儘管已接受過抗 C5 治療,但仍患有 PNH 和貧血的成年人,並得到針對補體抑制劑天真患者的Apply-PNH研究的支持1-5
在APPLY-PNH中,與繼續接受抗C5治療的患者相比,改用Fabhalta的患者的血紅蛋白水平升高幅度大於2 g/dL(82.3%對0%),血紅蛋白水平升高於12 g/dL(67.7%對0%)1,2
Fabhalta 現在可用於先前接受過治療和未接受治療的患者,它是唯一獲得美國食品藥品管理局批准的免疫系統補體途徑的 B 因子抑制劑,可驅動 PNH1,6 中補體介導的溶血
PNH 是一種慢性罕見的血液病,仍有大量需求未得到滿足;儘管進行了抗C5治療,但仍有很大一部分患者仍處於貧血狀態,依賴輸血7,8
Fabhalta 開發計劃的後期階段正在多種補體介導條件下進行
新澤西州東漢諾威,2023 年 12 月 5 日 /PRNewswire/ — 諾華今天宣佈,美國食品藥品監督管理局 (FDA) 批准將 Fabhalta (iptacopan) 作爲首款用於治療成人陣發性夜間血紅蛋白尿 (PNH) 1 的口服單一療法。Fabhalta 是一種 B 因子抑制劑,在免疫系統的替代補體途徑中起作用,全面控制血管內外的紅細胞 (RBC) 破壞(血管內和血管外溶血 [IVH 和 EVH])。在臨床試驗中,使用Fabhalta治療會增加大多數患者的血紅蛋白水平(在沒有輸血紅細胞的情況下比基線增加2 g/dL),在APPLY-PNH中,幾乎所有接受Fabhalta治療的患者都沒有接受輸血1-5。
在此處體驗完整的交互式多渠道新聞稿:
希望之城血液學和造血細胞移植系臨床教授、MRCP醫學博士Vinod Pullarkat說:“具有明顯安全性的有效口服治療可以改變醫生的做法,並有助於減輕PNH患者的負擔。”“在臨床研究中,iptacopan在血紅蛋白改善方面優於抗C5藥物,在沒有紅細胞輸血和避免輸血的情況下,對補體抑制劑天真的個體也很有效,因爲無需輸血即可增加具有臨床意義的血紅蛋白水平。”
美國食品藥品管理局的批准是基於針對殘留貧血(血紅蛋白 < 10 g/dL)患者的III期APPLY-PNH試驗,儘管之前接受了抗C5治療,但改用了Fabhalta。與繼續接受抗C5治療的患者相比,Fabhalta在改善血紅蛋白方面表現出優於繼續接受抗C5治療的患者1,2。針對補體抑制劑未成熟患者的III期APPOINT-PNH研究也支持了批准1,3。APPLY-PNH和APPOINT-PNH試驗中的24周核心治療期分別顯示1-3:
在沒有輸血的情況下,血紅蛋白水平持續升高於基線水平≥2 g/dLA的患者:82.3%有抗C5經驗的Fabhalta患者有反應,而抗C5的患者反應爲0%(差異爲81.5% b,P<0.0001);使用Fabhalta的補體抑制劑未成熟的患者中有77.5%達到了這一結果(靈敏度分析顯示爲87.5% c)1-3。
在沒有輸血的情況下,血紅蛋白水平持續≥12 g/dLA的患者:67.7%有抗C5經驗的Fabhalta患者有反應,而抗C5的患者反應爲0%(差異爲66.6% b,P<0.0001)1-2。
避免輸血的患者,e:有抗C5經驗的Fabhalta患者的輸血規避率爲95.2%,而抗C5患者的輸血規避率爲45.7%(差異爲49.5% b,P<0.0001)1-2。
在APPLY-PNH試驗中,Fabhalta與抗C5藥物最常報告的不良反應(AR)(≥10%)是:頭痛(19%對3%)、鼻咽炎(16%對17%)、腹瀉(15%對6%)、腹痛(15%對3%)、細菌感染(11%對11%)、噁心(10%對3%)和病毒感染(10% 對 31%)1,2。在APPOINT-PNH試驗中,最常報告的ARs(≥10%)是頭痛(28%)、病毒感染(18%)、鼻咽炎(15%)和皮疹(10%)1,3。在APPLY-PNH中,據報道,接受Fabhalta治療的兩例(3%)PNH患者出現了嚴重的抗逆轉錄病毒感染,其中包括腎盂腎炎、尿路感染和COVID-191,2。在Appoint-PNH中,報告了兩名(5%)接受Fabhalta治療的PNH患者出現嚴重的抗逆轉錄病毒感染,其中包括 COVID-19 和細菌性肺炎1,3。Fabhalta 可能導致由封裝細菌引起的嚴重感染,只能通過要求爲封裝細菌接種疫苗的風險評估和緩解策略 (REMS) 才能獲得1。
患有 PNH 的人有獲得性突變,這使得紅細胞容易被補體系統過早破壞6,8。PNH 的特徵是溶血、骨髓衰竭和血栓形成,其組合和嚴重程度各不相同 6-8。現有的C5抑制劑療法,以輸液的形式給藥,可能會使PNH症狀無法控制7,8。在接受抗C5治療的患者中,多達88%的患者可能患有持續性貧血,其中超過三分之一的患者每年至少需要輸血一次7,8。
諾華美國總裁維克多·布爾託說:“對於PNH患者、他們的親人和照顧他們的醫療保健提供者來說,美國批准Fabhalta是一個非同尋常的時刻。”“這種新的、有效的口服藥物可能意味着患者可以重置他們對患有PNH的期望,PNH是一種改變生活的慢性血液病。隨着諾華繼續關注患者需求未得到滿足的疾病,我們正在探索Fabhalta在其他補體介導疾病中的潛力,其最終目標是爲患者推動有意義的改變。”
Fabhalta由諾華發現和開發,預計將於12月在美國上市。目前,世界各地正在對PNH的Fabhalta進行其他監管申報和審查。
a在第 126 天和第 168 天之間進行評估。badJusted 比例差異。c敏感度分析納入了當地實驗室在沒有中央實驗室時的數據。d在第 14 天和第 168 天之間進行評估。避免輸血被定義爲在第 14 天至第 168 天之間不進行包裝紅細胞輸血。finsopharyngitis 包含:過敏性鼻炎、上呼吸道感染、咽部炎症、鼻炎。細菌感染包含:腎盂腎炎、尿路感染、細菌支氣管炎、支氣管炎嗜血桿菌、膽囊炎、毛囊炎、蜂窩組織炎、細菌性關節炎、敗血症、克雷伯氏菌感染、葡萄球菌感染、假單胞菌感染、hordeolum、肺炎細菌。病毒感染包含:COVID-19、帶狀皰疹、口腔皰疹、甲型流感病毒檢測陽性、流感。JRash:過敏性皮炎、痤瘡、紅斑多形性皮疹、斑丘疹、紅斑皮疹。
指示
FABHALTA 是一種處方藥,用於治療患有陣發性夜間血紅蛋白尿(PNH)的成年人。
目前尚不清楚FABHALTA對兒童是否安全有效。
重要安全信息
FABHALTA是一種影響部分免疫系統並可能降低人體抵抗感染能力的藥物。FABHALTA 增加了被封裝的細菌(包括肺炎鏈球菌、腦膜炎奈瑟菌和乙型流感嗜血桿菌)引起的嚴重感染的機會。如果不及早發現和治療,這些嚴重的感染可能很快就會危及生命或死亡。患者必須在開始使用 FABHALTA 前至少 2 周完成或更新針對這些細菌的疫苗接種。如果患者尚未完成這些疫苗接種並且必須立即開始FABHALTA治療,則他們應儘快接種所需的疫苗。如果患者沒有接種疫苗並且必須立即開始使用FABHALTA,那麼他們還應該按照醫生的指示服用抗生素。如果患者過去接種過這些細菌的疫苗,則在開始使用FABHALTA之前,他們可能需要額外的疫苗接種。他們的醫生將決定他們是否需要額外的疫苗接種。疫苗不能預防所有由封裝細菌引起的感染。如果患者出現以下任何嚴重感染的體徵和症狀,應立即致電醫生或接受緊急醫療護理:發燒伴有或沒有顫抖或發冷;發燒伴胸痛和咳嗽;發燒伴心率高;頭痛和發燒;精神錯亂;皮膚髮熱;發燒伴呼吸困難/呼吸急促;頭痛伴有噁心或嘔吐;頭痛伴有流感樣症狀;或者眼睛對光線敏感。醫生將向患者提供一份關於嚴重感染風險的患者安全卡。患者在治療期間以及最後一次服用 FABHALTA 後的 2 周內必須隨身攜帶。在他們最後一次服用FABHALTA後,嚴重感染的風險可能會持續數週。對於患者來說,向任何治療他們的醫生出示這張卡很重要。這將幫助醫生快速診斷和治療患者。
FABHALTA只能通過一項名爲FABHALTA風險評估和緩解策略(REMS)的計劃獲得。在患者服用FABHALTA之前,他們的醫生必須註冊FABHALTA REMS計劃,就某些細菌引起的嚴重感染的風險向患者提供諮詢,向患者提供有關嚴重感染症狀的信息,確保患者接種了由封裝細菌引起的嚴重感染的疫苗,如果他們需要立即開始使用FABHALTA且不了解最新的疫苗接種,還要向患者提供患者安全卡嚴重感染的風險。
由於FABHALTA可能會增加患者的膽固醇和甘油三酯,因此他們的醫生將定期進行血液檢查以檢查其水平。
如果患者對 FABHALTA 或 FABHALTA 中的任何成分過敏,則不應服用 FABHALTA。如果患者在開始使用 FABHALTA 時患有由封裝細菌(包括肺炎鏈球菌、腦膜炎奈瑟菌或 B 型流感嗜血桿菌)引起的嚴重感染,則不應服用 FABHALTA。
在服用FABHALTA之前,患者應告知醫生他們所有的健康狀況,包括他們是否有感染或發燒、有腎臟或肝臟問題、是否懷孕或計劃懷孕(尚不清楚FABHALTA是否會傷害未出生的嬰兒),或者正在母乳餵養或計劃母乳餵養,因爲尚不清楚FABHALTA是否會進入母乳。患者在治療期間和最後一劑FABHALTA後的5天內不應進行母乳餵養。
患者應告知醫生他們服用的所有藥物,包括處方藥和非處方藥、維生素和草藥補充劑。將 FABHALTA 與某些其他藥物一起服用可能會影響 FABHALTA 的作用方式,並可能產生副作用。患者應該知道他們服用的藥物和接種的疫苗。患者應保留一份清單,以便在獲得新藥時向醫生和藥劑師展示。
如果患者患有 PNH 並停止服用 FABHALTA,則在停用 FABHALTA 後,他們的醫生需要對他們進行至少兩週的密切監測。由於 PNH,停止使用 FABHALTA 治療可能會導致紅細胞分解。紅細胞分解可能導致的症狀或問題包括血液中的血紅蛋白水平降低;尿液中的血液;呼吸急促;吞嚥困難;疲勞;胃部(腹部)疼痛;血塊、中風和心臟病發作;以及勃起功能障礙(ED)。重要的是,患者必須嚴格按照醫生的指示服用FABHALTA,以降低由於 PNH 導致紅細胞分解的可能性。
FABHALTA 最常見的副作用包括頭痛;鼻塞、流鼻涕、咳嗽、打噴嚏和喉嚨痛(鼻咽炎);腹瀉;胃痛(腹部);感染(病毒和細菌);噁心和皮疹。